Trial record 16 of 610 for:    Open Studies | "Pregnancy Complications"

Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by HaEmek Medical Center, Israel.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT01507974
First received: January 4, 2012
Last updated: January 8, 2012
Last verified: January 2012
  Purpose

Urinary tract infection is the most common bacterial infection during pregnancy. Asymptomatic bacteriuria is the most common infection, in up to 8% of the population. Symptomatic infection may cause cystitis or cause pyelonephritis.

Among pregnant women with recurrent bacteriuria, preventive antibiotic treatment has been found to be efficacious in reducing the bacteriuria rate and the complications.

the changes of the urinary tract which appear during pregnancy usually resolve up to 3 months post-partum.

The purpose of this study is to examine the efficacy of preventive antibiotic treatment during the puerperium.


Condition Intervention
Pregnancy Complications
Drug: Preventive antibiotic treatment- NITROFURANTOIN
Drug: Preventive antibiotic treatment- CEPHALEXIN
Drug: PREVENTIVE TREATMENT- AMOXICILLIN
Drug: PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM
Drug: PREVENTIVE TREATMENT- CEFUROXIME
Drug: PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • Urinary tract complications [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: January 2012
Estimated Study Completion Date: January 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: control arm
The women in this arm will stop the preventive antibiotic treatment after the delivery
Active Comparator: preventive antibiotic treatment
The women in this arm will continue the preventive antibiotic treatment after the delivery to 6 weeks
Drug: Preventive antibiotic treatment- NITROFURANTOIN
P.O NITROFURANTOIN 100 mg per day for 6 weeks
Drug: Preventive antibiotic treatment- CEPHALEXIN
P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
Drug: PREVENTIVE TREATMENT- AMOXICILLIN
P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
Drug: PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM
P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
Drug: PREVENTIVE TREATMENT- CEFUROXIME
P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
Drug: PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM
P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
No Intervention: FOLLOW UP ARM
this arm will include women who do not want to participate in the study, and those women will stop the preventive treatment after delivery, and THE INVESTIGATORS will contact those women to collect information regarding their health status post partum

Detailed Description:

During pregnancy functional modifications in the urinary tract influence the function of the urinary tract system. Those changes raise the risk of urinary tract infections. The most common bacterial infections during pregnancy are urinary tract infections. Actually, asymptomatic bacteriuria is the most common infection in up to 8% of the population. Symptomatic infection may cause cystitis or include the renal calyces and parenchyma and cause pyelonephritis. There are few common protocols for bacteriuria treatment. The recurrence rate after treatment is 30%. Preventive treatment with nitrofurantoin has been demonstrated to be effective, although there is a small risk to acute respiratory distress which resolved with cessation of the treatment. Renal infection is the most common serious infection during pregnancy. Complication of renal infection can lead to ARDS or urosepsis. Renal infection usually develops during the second trimester and has been related to prim parity and young women.

About 20% of women will deteriorate to renal insufficiency. 30-40% of cases will be followed with recurrent bacteriuria later on, for this reason, a preventive treatment is recommended until delivery. In previous studies the preventive treatment reduced the bacteriuria rate from 38% to 8%.

After delivery, the morphological changes including edema, bladder hyperemia and a raise in the urinary volume, pass away up to 3 months post partum. There is only slight information regarding the rate of bacteriuria during puerperium, most of the information relates to the early puerperium period. In addition, the consequences of such infection are unknown.

The aim of this study is to estimate the efficacy of preventive antibiotic treatment during the puerperium.

Objectives

  1. To estimate the rate of bacteriuria and other urinary tract infections during the puerperium among women with preventive treatment during pregnancy
  2. To evaluate the efficacy of preventive treatment during the puerperium Hypothesis: The pregnancy modifications which cause more urinary tract infections during pregnancy, exist also during the puerperium, and can cause complications Study design Prospective, randomized, open label Study population: Pregnant women with two or more episodes of bacteriuria or one episode of pyelonephritis, whom are treated with prophylactic antibiotic Study period From 6 weeks after delivery The study size has been determined according to a reduction in the bacteriuria rate following preventive treatment from 38% to 8%. Basing on that fact, each group has to include 37 women, to get a 80% power with α=0.05.

Study protocol: women will be randomized at recruitment. Demographic and obstetrical data will be collected. The women in the treatment group will continue the prophylactic treatment after the delivery, for 6 weeks. If the woman breastfeeds, the treatment will be fitted to the situation. Urine culture will be collected the morning following the delivery , 3 and 6 weeks post delivery. The women will be invited to the high risk unit for follow up after 3 and 6 weeks. Details regarding bacteriuria, urinary tract infections, pyelonephritis and admissions for related complications will be collected.

The study was approved by the local Helsinki committee. Time table Duration: one year

  Eligibility

Ages Eligible for Study:   16 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pregnant women with two or more episodes of bacteriuria or one episode of pyelonephritis during pregnancy, whom are treated with preventive antibiotic treatment

Exclusion Criteria:

  • Women with malformations of the urinary tract
  • women with risk factors to urinary tract infections, for example DIABETES MELLITUS, REFLUX.
  • Women with urinary tract infection caused by resistant bacteria (to conventional treatment)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01507974

Locations
Israel
Dep of OG/GYN, Emek Medical Center Not yet recruiting
Afula, Israel
Contact: MEIRAV BRAVERMAN, MD    0509384595    meiraval@clalit.org.il   
Principal Investigator: Meirav Braverman, MD         
Sponsors and Collaborators
HaEmek Medical Center, Israel
  More Information

No publications provided

Responsible Party: HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier: NCT01507974     History of Changes
Other Study ID Numbers: 0068-11-EMC
Study First Received: January 4, 2012
Last Updated: January 8, 2012
Health Authority: Israel: Ministry of Health

Keywords provided by HaEmek Medical Center, Israel:
preventive
antibiotic treatment
urinary tract infection
pregnancy
puerperium

Additional relevant MeSH terms:
Pregnancy Complications
Urinary Tract Infections
Infection
Urologic Diseases
Amoxicillin
Anti-Bacterial Agents
Cefuroxime
Cefuroxime axetil
Cephalexin
Amoxicillin-Potassium Clavulanate Combination
Clavulanic Acids
Clavulanic Acid
Nitrofurantoin
Sulfamethoxazole
Trimethoprim
Trimethoprim-Sulfamethoxazole Combination
Antibiotics, Antitubercular
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents
Anti-Infective Agents, Urinary
Renal Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 11, 2014